Oral hymecromone decreases hyaluronan in human study participants

Oral hymecromone decreases hyaluronan in human study participants

BACKGROUND Hyaluronan (HA), an extracellular matrix glycosaminoglycan, has been implicated in the pathophysiology of COVID-19 infection, pulmonary hypertension, pulmonary fibrosis, and other diseases, but is not targeted by any approved drugs. We asked whether hymecromone (4-methylumbelliferone [4-M...

Full description

Bibliographic Details
Main Authors: Joelle I. Rosser, Nadine Nagy, Riya Goel, Gernot Kaber, Sally Demirdjian, Jamie Saxena, Jennifer B. Bollyky, Adam R. Frymoyer, Ana E. Pacheco-Navarro, Elizabeth B. Burgener, Jayakumar Rajadas, Zhe Wang, Olga Arbach, Colleen E. Dunn, Anissa Kalinowski, Carlos E. Milla, Paul L. Bollyky
Format: Article
Language:English
Published: American Society for Clinical Investigation 2022-05-01
Series:The Journal of Clinical Investigation
Subjects:
Inflammation
Online Access:https://doi.org/10.1172/JCI157983

Internet

https://doi.org/10.1172/JCI157983

Similar Items